Coacervate micro and/or nano droplets and hydrogels
A composition includes a plurality of coacervate micro and/or nanodroplets of oxidized alginate and a methacrylated gelatin.
1. A composition comprising:
a plurality of coacervate microdroplets and/or nanodroplets that include an oxidized alginate and a methacrylated gelatin, and at least one bioactive agent incorporated in the plurality of coacervate microdroplets and/or nanodroplets, wherein the oxidized alginate has an oxidation percentage of at least 10% of uronic acid units of alginate and the methacrylated gelatin has a methacrylation percentage of about 10% to about 99% of amine groups of gelatin.
2. The composition of claim 1 , wherein the oxidized alginate has an oxidation percentage up to 50% of uronic acid units of alginate.
3. The composition of claim 2 , wherein the oxidized alginate is methacrylated and has a methacrylation percentage up to 45% of alginate carboxylic acid reactive groups.
4. The composition of claim 1 , further comprising a cytocompatible hydrogel matrix in which the coacervate microdroplets and/or nanodroplets are suspended.
5. The composition of claim 4 , wherein the hydrogel matrix is cross-linked.
6. The composition of claim 4 , wherein the hydrogel matrix includes a plurality of cells and the plurality of coacervate microdroplets and/or nanodroplets provide controlled release of the bioactive agent to the plurality of cells.
7. The composition of claim 6 , wherein the bioactive agent comprises BMP-2 and the cells comprise progenitor cells.
8. The composition of claim 4 , wherein the hydrogel further includes photocrosslinkable heparin.
9. A coacervate hydrogel comprising:
crosslinked oxidized alginate and methacrylated gelatin that form a hydrogel matrix and a plurality of coacervate microdroplets and/or nanodroplets suspended in the matrix, wherein the oxidized alginate has an oxidation percentage of at least 10% of uronic acid units of alginate and the methacrylated gelatin has a methacrylation percentage of about 10% to about 99% of amine groups of gelatin.
10. The hydrogel of claim 9 , wherein at least one bioactive agent is incorporated in the coacervate microdroplets and/or nanodroplets and/or matrix.
11. The hydrogel of claim 9 , wherein the oxidized alginate has an oxidation percentage up to 50% of uronic acid units of alginate.
12. The hydrogel of claim 10 , wherein the oxidized alginate is methacrylated and has a methacrylation percentage up to 45% of alginate carboxylic acid reactive groups.
13. The hydrogel of claim 10 , wherein the hydrogel matrix includes a plurality of cells and the plurality of coacervate microdroplets and/or nanodroplets provide controlled release of the bioactive agent to the plurality of cells.
14. The hydrogel of claim 13 , wherein the bioactive agent comprises BMP-2 and the cells comprise hMSCs.
15. A coacervate hydrogel comprising:
a crosslinked oxidized methacrylated alginate and a methacrylated gelatin that form a hydrogel matrix and a plurality of coacervate microdroplets and/or nanodroplets, wherein the oxidized methacrylated alginate has an oxidation percentage of 10% up to 50% of uronic acid units and a methacrylation percentage up to 45% of carboxylic acid reactive groups of alginate, the methacrylated gelatin has a methacrylation percentage of at least about 10% to about 99% of amine groups of alginate.
16. The hydrogel of claim 15 , further comprising at least one bioactive agent incorporated in the microdroplets and/or nanodroplets and/or matrix.
17. The hydrogel of claim 16 , wherein the hydrogel matrix includes a plurality of cells and the plurality of coacervate microdroplets and/or nanodroplets provide controlled release of the bioactive agent to the plurality of cells.
18. The hydrogel of claim 17 , wherein the bioactive agent comprises BMP-2 and the cells comprise hMSCs.